Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

CONCLUSION: Patients with resectable/borderline resectable PDAC who receive neoadjuvant therapy have longer OS and RFS relative to those who receive upfront surgery.PMID:38676648 | DOI:10.1177/00031348241250043

Source: The American Surgeon - April 27, 2024 Category: Surgery Authors: Jesse K Kelley Hordur Kolbeinsson Sreenivasa Chandana Benjamin Eastburg Austin Frisch Jessica Parker G Paul Wright M Mura Assifi Mathew Chung Source Type: research